Article

EGFR and tyrosine kinase inhibitor interactions probed by hydrogen-deuterium exchange and mass spectrometry (HDX-MS)

2024-10-17

Abstract excerpt

<h4>Summary</h4> EGFR is one of the primary drug targets for treating non-small cell lung cancer (NSCLC) patients carrying EGFR oncogenic mutations in the tyrosine kinase domain (TKD). Such patients typically receive tyrosine kinase inhibitors (TKIs) to inhibit aberrant activation of EGFR; however, together with the appearance of the TKI-resistant mutations, TKIs’ severe side effects often limit their clinical us...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1d6deca3-0f64-577a-842a-686f1d0bd4c6
DOI: 10.1101/2024.10.14.618277

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

EGFR and tyrosine kinase inhibitor interactions probed by hydrogen-deuterium exchange and mass spectrometry (HDX-MS)DOI 10.1101/2024.10.14.618277Read

Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR.Semantic proximity Read

Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.Semantic proximity Read

Uncovering the Structural and Binding Insights of Dual Inhibitors Simultaneously Targeting Two Distinct Sites on EGFR Kinase.Semantic proximity Read

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds.Semantic proximity Read

Structural basis for the selectivity of 3rd generation EGFR inhibitors: a molecular dynamics study.Semantic proximity Read

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.Semantic proximity Read

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.Semantic proximity Read

Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.Semantic proximity Read

Computational identification of new TKI as potential noncovalent reversible EGFRL858R/T790M inhibitors: VHTS, molecular docking, DFT study and molecular dynamic simulation.Semantic proximity Read

The new N2, N4-diphenylpyridine-2,4-diamine deuterated derivatives as EGFR inhibitors to overcome C797S-mediated resistance.Semantic proximity Read

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.Semantic proximity Read

Comprehensive analysis and outcomes of hybridization of physiologically active heterocycles targeting epidermal growth factor receptor (EGFR).Semantic proximity Read